News of Note

News of Note

An Opioid Combo Falls Short in Depression

Topics: Depression | News of Note

Opioids have a bad name these days. But let’s not forget that they were once consid­ered a first-line treatment for depression before the discovery of MAOIs and tricy­clics in the 1950s. That history has been revived recently by buprenorphine, a par­tial opioid agonist that was fast-tracked by the FDA for treatment-resistant depression. Buprenorphi

Read More
News of Note

Brexanolone: A New Treatment for Postpartum Depression

Topics: News of Note

There is a need for rapid treatment in postpartum depression, as each month of this potentially severe condition can take a toll on infant development. That is why brexanolone (Zulresso), which was recently fast-tracked for approval by the FDA, is causing such a splash. Brexanolone is a neurosteroid that activates GABAA receptors. It was originally d

Read More
News of Note

FDA Approves Lucemyra—But Is It Better Than Clonidine?

Topics: News of Note

On May 16, 2018, the FDA announced its approval of Lucemyra (lofexidine) as a drug to help patients withdraw from opioids. Like clonidine, lofexidine is an alpha-2 agonist, but it is touted as causing less orthostatic hypotension and therefore being somewhat safer to use. To put this in perspective, it’s important to note that buprenorphine is the

Read More
News of Note

New Approvals for TMS

Topics: Brain Devices | News of Note

We know that transcranial magnetic stimulation (TMS) works for treatment-resistant depression (TRD) (see TCPR July/August 2017 for our most recent coverage), but one disadvantage is the length of the treatment sessions. We also don’t know if TMS works for other disorders. Recently, the FDA granted new approvals that address both these issues. One a

Read More
News of Note

Jornay PM Nighttime Stimulant for Next-Morning Effect

Topics: ADHD | News of Note | Sleep Disorders

Prescribing bedtime stimulants sounds like a recipe for a bad night’s sleep. But the FDA recently approved Jornay PM, which is an extended release (ER) formulation of methylphenidate that is, in fact, dosed at night. Approved for kids age 6 and older, Jornay PM has an extremely delayed onset of effect of 10 hours. This means kids can take it at aro

Read More
News of Note

FDA Approves First Drug to Treat Tardive Dyskinesia

Topics: News of Note | Psychopharmacology

On April 11, the U.S. Food and Drug Administration approved Ingrezza (valbenazine) for the treatment of tardive dyskinesia (TD), a disabling movement disorder that afflicts 10%–20% of people on chronic antipsychotic ­medication. The approval was based on a clinical trial in which 234 patients with moderate to severe TD were randomly assigned to a

Read More
News of Note

A Kratom Update

Topics: Addiction | News of Note | Substance Abuse

If you have not yet heard of kratom (usually pronounced kray-tom or krah-tom), consider this an introduction to an herbal supplement that will likely be popping up in your newsfeeds with increasing frequency. Kratom (Mitragyna speciosa) is a tropical evergreen tree in the coffee family that has been used for centuries in Southeast Asia to boost energy a

Read More
News of Note

Concerta: Brand vs Generic

Topics: Child Psychiatry | News of Note | Pharmaceutical Industry | Psychopharmacology

In November 2016, the FDA announced that it was requiring two companies to withdraw their generic versions of Concerta (OROS methylphenidate) because of efficacy concerns. Such actions are quite unusual, and when they occur, they tend to shake doctors’ confidence in the generic drug system—which branded drug companies are often eager to encourage. B

Read More
Article

Before You Write That Prescription: Guidelines for Ordering Lab Tests

Topics: Laboratory Testing in Psychiatry | News of Note | Practice Tools and Tips | Psychopharmacology Tips

Mental health clinicians often ask for a single, black-and-white answer to the question: Which lab tests should I order before starting this particular medication? Inevitably, the answer is that it depends. However, there are some guidelines that are useful. When it comes to ordering lab tests, it sometimes feels like we are “damned if we do, and d

Read More
News of Note

Cariprazine (Vraylar): A drug for negative symptoms? Don’t be positive.

Topics: Antipsychotics | News of Note | Psychopharmacology Tips

Read More
News of Note

Rexulti for Schizophrenia and MDD: Is It Abilify, Round 2?

Topics: Antidepressants | Depressive Disorder | News of Note

Read More
News of Note

Powdered Alcohol? It Could Hit Stores This Summer

Topics: News of Note

Read More
News of Note

FDA Warns About Combining Chantix and Alcohol

Topics: News of Note | Smoking Cessation Agents

Read More
News of Note

Saphris Approved for Pediatric Bipolar Disorder—What Do the Data Show?

Topics: Antipsychotics | Bipolar Disorder | Child Psychiatry | News of Note

Read More
News of Note

FDA Approves Vyvanse to Treat Binge-Eating Disorder

Topics: Eating Disorders | News of Note

Read More
News of Note

How Deadly is Alcohol Poisoning? Very.

Topics: Addiction | News of Note

Read More
News of Note

FDA Issues Alert for Geodon

Topics: Antipsychotics | News of Note

Read More
News of Note

FDA Approves New Weight Drug

Topics: News of Note | Weight Loss Medications

Read More
News of Note

FDA Notice: Be Wary of Some Generic Versions of Concerta

Topics: ADHD | News of Note | Pharmaceutical Industry

Read More
News of Note

Omega Fatty Acids Might Help Kids with Attention Deficits

Topics: ADHD | Child Psychiatry | News of Note

Read More